Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Esther A. Peterson; Eirini Pectasides; Shabana Shabbeer; Lisa Wiechmann; Joseph A. Sparano; Paraic A. Kenny

doi:10.1186/2162-3619-2-25

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Esther A. Peterson
, Eirini Pectasides
, Shabana Shabbeer
, Lisa Wiechmann
, Joseph A. Sparano
, Paraic A. Kenny

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

Original language	English (US)
Article number	25
Journal	Experimental Hematology and Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1186/2162-3619-2-25
State	Published - Sep 8 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Amphiregulin
Breast cancer
Epidermal growth factor receptor
Serum biomarker

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1186/2162-3619-2-25

Cite this

@article{d2faad7d54c9466cbede7d3948ed1539,

title = "Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls",

abstract = "Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.",

keywords = "Amphiregulin, Breast cancer, Epidermal growth factor receptor, Serum biomarker",

author = "Peterson, \{Esther A.\} and Eirini Pectasides and Shabana Shabbeer and Lisa Wiechmann and Sparano, \{Joseph A.\} and Kenny, \{Paraic A.\}",

note = "Funding Information: This study was supported by a pilot project grant from the Albert Einstein Cancer Center, Susan G. Komen for the Cure (KG100888 to PK) and by the American Cancer Society (RSG-12-267-01-TBE to PK). EAP was supported by an IRACDA K12 training grant (1K12GM102779-01).",

year = "2013",

month = sep,

day = "8",

doi = "10.1186/2162-3619-2-25",

language = "English (US)",

volume = "2",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

AU - Peterson, Esther A.

AU - Pectasides, Eirini

AU - Shabbeer, Shabana

AU - Wiechmann, Lisa

AU - Sparano, Joseph A.

AU - Kenny, Paraic A.

N1 - Funding Information: This study was supported by a pilot project grant from the Albert Einstein Cancer Center, Susan G. Komen for the Cure (KG100888 to PK) and by the American Cancer Society (RSG-12-267-01-TBE to PK). EAP was supported by an IRACDA K12 training grant (1K12GM102779-01).

PY - 2013/9/8

Y1 - 2013/9/8

N2 - Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

AB - Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

KW - Amphiregulin

KW - Breast cancer

KW - Epidermal growth factor receptor

KW - Serum biomarker

UR - https://www.scopus.com/pages/publications/84978024376

UR - https://www.scopus.com/pages/publications/84978024376#tab=citedBy

U2 - 10.1186/2162-3619-2-25

DO - 10.1186/2162-3619-2-25

M3 - Article

AN - SCOPUS:84978024376

SN - 2162-3619

VL - 2

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

IS - 1

M1 - 25

ER -

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this